Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B2 | P37059 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | KEAP1 | Q14145 | 4/20 | 0.58 |
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.56 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.55 |
| ▸ | SQSTM1 | Q13501 | 1/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.52 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.51 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.51 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.51 |
| ▸ | APP | P05067 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7594141 | 0.90 | LMNA (0.67) | LMNAKEAP1FFAR4NFE2L2SQSTM1 | |
| SCHEMBL27270544 | 0.83 | LMNA (0.59) | LMNAKEAP1FFAR4NFE2L2SQSTM1 | |
| SCHEMBL1259968 | 0.80 | HSD17B2 (0.67) | HSD17B2LMNAAPPMAPT | |
| SCHEMBL29978640 | 0.80 | HSD17B2 (0.67) | HSD17B2KEAP1FFAR4APP | |
| SCHEMBL29978689 | 0.80 | HSD17B2 (1.00) | HSD17B2FFAR4APPMAPT | |
| SCHEMBL6560643 | 0.78 | KEAP1 (0.70) | LMNAKEAP1FFAR4NFE2L2SQSTM1 | |
| SCHEMBL23014076 | 0.77 | ALDH1A1 (0.71) | LMNAKEAP1FFAR4NFE2L2SQSTM1 | |
| SCHEMBL17340514 | 0.77 | HSD17B2 (0.75) | HSD17B2LMNAFFAR4APPMAPT | |
| SCHEMBL9931194 | 0.77 | CCR2 (0.72) | TP53 | |
| SCHEMBL7579883 | 0.77 | CYP19A1 (0.68) | LMNAFFAR4CYP19A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11459287-B1 | Arene-immobilized ru(II)TsDPEN complexes: synthesis and applications to the asymetric transfer hydrogenation of ketones | KING ABDULAZIZ UNIVERSITY (SA) | 2022-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11459287-B1 | Arene-immobilized ru(II)TsDPEN complexes: synthesis and applications to the asymetric transfer hydrogenation of ketones | ADH1A, KLF10, TKT | HSD17B2 315/4885LMNA 3987/4885KEAP1 2087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.